Treatment of bacterial vaginosis: a randomised controlled trial

Funded Activity Summary

The objective of this research project is to determine if the treatment of Bacterial Vaginosis (BV) can be improved. Bacterial vaginosis is one of the most common causes of vaginal discharge in women. It can also have serious consequences, such as premature labour and can also increase the risk of HIV transmission. These complication cost communities many millions of dollars; for example in the US it is estimated that premature labour caused by BV alone costs about 1 billion dollars a year. The currently recommended treatment for BV works well initially (first month about 80% respond) but by 12 months most (60%) have relapsed. This randomised clinical study is investigating new ways to treat BV. The currently recommended arm of treatment (antibiotic metronidazole) is being compared to two other treatments. The second arm of the study involves the use of two antibiotics at once (metronidazole and clindamycin) and the third arm involves the use of a bacterial (lactobacilli) and oestrogen. Lactobacilli are bacteria that may help maintain the normal bacterial (and there by prevent relapse of BV) and oestrogen may have a similar effect. If either of these treatments improved the longer term treatment of BV, very significant benefits would flow to affected women and the community as a whole.

Funded Activity Details

Start Date: 01-01-2007

End Date: 01-01-2009

Funding Scheme: NHMRC Project Grants

Funding Amount: $265,757.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Venereology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Adverse Pregnancy Outcomes | Antibiotic treatment | Bacterial Vaginosis | Clinical Medicine | Prevention of HIV transmission | Randomised Controlled Trial

Related Links